A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours

BACKGROUND: This is a first-in-human study with TAS-119, an Aurora A kinase (AurA) inhibitor. METHODS: Patients with advanced, refractory, solid tumours were enrolled into 5 dose escalation cohorts (70–300 mg BID, 4 days on/3 days off, 3 out of 4 weeks or 4 out of 4 weeks). The expansion part consis...

Descripción completa

Detalles Bibliográficos
Autores principales: Robbrecht, Debbie G. J., Lopez, Juanita, Calvo, Emiliano, He, Xiaomin, Hiroshi, Hirai, Soni, Nital, Cook, Natalie, Dowlati, Afshin, Fasolo, Angelica, Moreno, Victor, Eskens, Ferry A. L. M., de Bono, Johann S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852567/
https://www.ncbi.nlm.nih.gov/pubmed/33020594
http://dx.doi.org/10.1038/s41416-020-01100-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852567/
https://www.ncbi.nlm.nih.gov/pubmed/33020594
http://dx.doi.org/10.1038/s41416-020-01100-3

Ejemplares similares